Darwin Global Management’s Pfizer PFE Stock Holding History

Darwin Global Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,697,762	Closed	-$455M	–	9
2021 Q4	$455M	Buy	+7,697,762	New	+$381M	69.44%	1

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Darwin Global Management's PFE Position: Q1 2022 in Review

Darwin Global Management sold out of Pfizer (PFE) in Q1 2022, closing a stake of 7,697,762 shares — an estimated $455M sold.

Darwin Global Management first reported a position in PFE in Q4 2021 and held it in 1 quarter. The position peaked at $455M in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Darwin Global Management reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Darwin Global Management sold 7,697,762 Pfizer shares in Q1 2022, an estimated $455M.
Darwin Global Management first reported a position in Pfizer in Q4 2021 and held it in 1 quarter.
Darwin Global Management's Pfizer position peaked at $455M in Q4 2021.
3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Darwin Global Management's 13F filing for Q1 2022, filed 16 May 2022.